Therapeutic targeting of subdural medulloblastomas using human neural stem cells expressing carboxylesterase

Cancer Gene Therapy

Volumn 18, Issue 11, 2011, Pages 817-824

  Lim, S H ^a   Choi, S A ^a   Lee, J Y ^a   Wang, K C ^a   Phi, J H ^a   Lee, D H ^a   Song, S H ^b   Song, J H ^b   Jin, X ^c   Kim, H ^c   Lee, H J ^d,e   Lim, I ^d   Kim, S U ^d,e   Kim, S K ^a  

^a Seoul National University Children's Hospital   (South Korea)

^b Seoul National University Bundang Hospital   (South Korea)

^c Korea University   (South Korea)

^d Chung Ang University College of Medicine   (South Korea)

^e UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

carboxylesterase; gene directed enzyme prodrug therapy; medulloblastoma; metastasis; neural stem cell; tumor tropism

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; CARBOXYLESTERASE; IRINOTECAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER LOCALIZATION; CELL MIGRATION; CONTROLLED STUDY; DRUG METABOLISM; DURA MATER; GENETIC ENGINEERING; HUMAN; HUMAN CELL; MALE; MEDULLOBLASTOMA; METASTASIS; MOUSE; NEURAL STEM CELL; NONHUMAN; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; STEM CELL GENE THERAPY; TREATMENT OUTCOME;

ANIMALS; CAMPTOTHECIN; CARBOXYLESTERASE; CEREBELLAR NEOPLASMS; GENE THERAPY; HUMANS; MALE; MEDULLOBLASTOMA; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOPLASM METASTASIS; NEURAL STEM CELLS; PROGNOSIS; RABBITS; RANDOM ALLOCATION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

ANIMALIA; MUS; MUS MUSCULUS; ORYCTOLAGUS CUNICULUS;

EID: 80054754775     PISSN: 09291903     EISSN: 14765500     Source Type: Journal    
DOI: 10.1038/cgt.2011.52     Document Type: Article

References (29)

1. Packer RJ, Sutton LN, Elterman R, Lange B, Goldwein J, Nicholson HS et al. Outcome for children with medulloblastoma treated with radiation and cisplatin, CCNU, and vincristine chemotherapy. J Neurosurg 1994; 81: 690-698. (Pubitemid 24328694)
2. David KM, Casey AT, Hayward RD, Harkness WF, Phipps K, Wade A. Medulloblastoma: is the 5-year survival rate improving? A review of 80 cases from a single institution. J Neurosurg 1997; 86: 13-21. (Pubitemid 27009969)
3. Habrand JL, De Crevoisier R. Radiation therapy in the management of childhood brain tumors. Childs NervSyst 2001; 17: 121-133. (Pubitemid 32203741)
4. Patrice SJ, Tarbell NJ, Goumnerova LC, Shrieve DC, Black PM, Loeffler JS. Results of radiosurgery in the management of recurrent and residual medulloblastoma. Pediatr Neurosurg 1995; 22: 197-203.
5. Graham ML, Herndon JEII, Casey JR. High-dose chemotherapy with autologous stem-cell rescue in patients with recurrent and high-risk pediatric brain tumors. J Clin Oncol 1997; 15: 1814-1823. (Pubitemid 27209509)
6. Mulhern RK, Palmer SL, Merchant TE, Wallace D, Kocak M, Brouwers P et al. Neurocognitive consequences of riskadapted therapy for childhood medulloblastoma. J Clin Oncol 2005; 23: 5511-5519.
7. Chang DY, Yoo SW, Hong Y, Kim S, Kim SJ, Yoon SH et al. The growth of brain tumors can be suppressed by multiple transplantation of mesenchymal stem cells expressing cytosine deaminase. Int J Cancer 2010; 127: 1975-1983.
8. Shimato S, Natsume A, Takeuchi H, Wakabayashi T, Fujii M, Ito M et al. Human neural stem cells target and deliver therapeutic gene to experimental leptomeningeal medulloblastoma. Gene Ther 2007; 14: 1132-1142. (Pubitemid 47086743)
9. Kim SK, Cargioli TG, Machluf M, Yang W, Sun Y, A-Hashem R et al. PEX-producing human neural stem cells inhibit tumor growth in a mouse glioma model. Clin Cancer Res 2005; 11: 5965-5970. (Pubitemid 41170327)
10. Aboody KS, Bush RA, Garcia E, Metz MZ, Najbauer J, Justus KA et al. Development of a tumor-selective approach to treat metastatic cancer. PLoS ONE 2006; 1: 1-10.
11. Joo KM, Park IH, Shin JY, Jin J, Kang BG, Kim MH et al. Human neural stem cells can target and deliver therapeutic genes to breast cancer brain metastases. Mol Ther 2009; 17: 570-575.
12. Danks MK, Yoon KJ, Bush RA, Remack JS, Wierdl M, Kim SU et al. Tumor-targeted enzyme/prodrug therapy mediates long-term disease-free survival of mice bearing disseminated neuroblastoma. Cancer Res 2007; 67: 22-25. (Pubitemid 46142755)
13. Dachs GU, Tupper J, Tozer GM. From bench to bedside for gene-directed enzyme prodrug therapy of cancer. Anticancer Drugs 2005; 16: 349-359. (Pubitemid 40434601)
14. McGregor LM, Spunt SL, Furman WL, Stewart CF, Schaiquevich P, Krailo MD et al. Phase 1 study of oxaliplatin and irinotecan in pediatric patients with refractory solid tumors: a children0s oncology group study. Cancer 2009; 115: 1765-1775.
15. Tanizawa A, Fujimori A, Fujimori Y, Pommier Y. Comparison of topoisomerase I inhibition, DNA damage, and cytotoxicity of camptothecin derivatives presently in clinical trials. J Natl Cancer Inst 1994; 86: 836-842. (Pubitemid 24164661)
16. Guemei AA, Cottrell J, Band R, Hehman H, Prudhomme M, Pavlov MV et al. Human plasma carboxylesterase and butyrylcholinesterase enzyme activity: correlations with SN-pharmacokinetics during a prolonged infusion of irinotecan. Cancer Chemother Pharmacol 2001; 47: 283-290. (Pubitemid 32640767)
17. Danks MK, Morton CL, Krull EJ, Cheshire PJ, Richmond LB, Naeve CW et al. Comparison of activation of CPT-11 by rabbit and human carboxylesterases for use in enzyme/prodrug therapy. Clin Cancer Res 1999; 5: 917-924. (Pubitemid 29180845)
18. Wagner LM, Guichard SM, Burger RA, Morton CL, Straign CM, Ashmun RA et al. Efficacy and toxicity of a virusdirected enzyme prodrug therapy purging method: preclinical assessment and application to bone marrow samples from neuroblastoma patients. Cancer Res 2002; 62: 5001-5007. (Pubitemid 34984426)
19. Wierdl M, Morton CL, Weeks JK, Danks MK, Harris LC, Potter PM. Sensitization of human tumor cells to CPT-11 via adenoviral-mediated delivery of a rabbit liver carboxylesterase. Cancer Res 2001; 61: 5078-5082. (Pubitemid 32681538)
20. Lee HJ, Kim KS, Kim EJ, Choi HB, Lee KH, Park IH et al. Brain transplantation of immortalized human neural stem cells promotes functional recovery in mouse intracerebral hemorrhage stroke model. Stem Cells 2007; 25: 1204-1212. (Pubitemid 46684880)
21. Kim SU, Nagai A, Nakagawa E, Choi HB, Bang JH, Lee HJ et al. Production and characterization of immortal human neural stem cell line with multipotent differentiation property. Methods Mol Biol 2008; 438: 103-121.
22. Kim SU, de Vellis J. Stem cell-based cell therapy in neurological diseases: a review. J Neurosci Res 2009; 87: 2183-2200.
23. Cargioli TG, Ugur HC, Ramakrishna N, Chan J, Black PM, Carroll RS. Establishment of an in vivo meningioma model with human telomerase reverse transcriptase. Neurosurgery 2007; 60: 750-759. (Pubitemid 46581146)
24. Schmidt KF, Ziu M, Schmidt NO, Vaghasia P, Cargioli TG, Doshi S et al. Volume reconstruction techniques improve the correlation between histological and in vivo tumor volume measurements in mouse models of human gliomas. J Neurooncol 2004; 68: 207-215. (Pubitemid 38878254)
25. Yin J, Kim JK, Moon JH, Beck S, Piao D, Jin X et al. hMSC-mediated concurrent delivery of endostatin and carboxylesterase to mouse xenografts suppresses glioma initiation and recurrence. Mol Ther 2011; 19: 1161-1169.
26. Gutierrez AA, Lemoine NR, Sikora K. Gene therapy for cancer. Lancet 1992; 339: 715-721.
27. Moolten FL. Drug sensitivity ('suicide') genes for selective cancer chemotherapy. Cancer Gene Ther 1994; 1: 279-287.
28. Wierdl M, Tsurkan L, Hyatt JL, Edwards CC, Hatfield MJ, Morton CL et al. An improved human carboxylesterase for enzyme/prodrug therapy with CPT-11. Cancer Gene Ther 2008; 15: 183-192. (Pubitemid 351240667)
29. Jurvansuu J, Zhao Y, Leung DS, Boulaire J, Yu YH, Ahmed S et al. Transmembrane protein 18 enhances the tropism of neural stem cells for glioma cells. Cancer Res 2008; 68: 4614-4622.